Double-blinded, placebo-controlled trial on intravenous l-alanyl-l-glutamine in the incidence of oral mucositis following chemoradiotherapy in patients with head-and-neck cancer

Conclusion: For patients with head-and-neck cancer receiving CRT, intravenous l-alanyl-l-glutamine may be an effective preventive measure to decrease the severity of mucositis.